Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors

Trial Profile

Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs ISA 101 (Primary) ; Nivolumab
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Primary endpoint has been met. (Overall Response Rate (ORR)), according to results presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 04 Sep 2017 Status changed from active, no longer recruiting to completed, according to an ISA Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top